H

Halozyme Therapeutics

HALO

55.050
USD
-0.233
(-0.42%)
Market Open
Volume
55,562
EPS
0
Div Yield
0
P/E
20
Market Cap
6,475,793,674
Related Instruments
A
AMRN
-0.06090
(-8.93%)
0.62120 USD
C
CRBP
-0.500
(-0.84%)
59.160 USD
G
GWRE
-1.150
(-0.77%)
148.920 USD
I
INSM
2.510
(3.45%)
75.330 USD
N
NBIX
11.660
(8.25%)
153.020 USD
S
SAGE
-1.21000
(-11.03%)
9.76000 USD
S
SRPT
1.650
(1.16%)
144.000 USD
V
VYGR
-0.59000
(-6.37%)
8.67000 USD
News

Title: Halozyme Therapeutics

Sector: Healthcare
Industry: Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.